Cryoport Systems specializes in advanced cryopreservation services through its IntegriCell™ platform, which is designed to optimize the quality and viability of leukapheresis-derived cell therapies. This technology employs state-of-the-art cryopreservation protocols that ensure the integrity of cellular materials, particularly within the critical 24-hour window post-collection. By utilizing a GMP-compliant, closed automated system, Cryoport minimizes contamination risks and enhances the reliability of the cryopreservation process. The standardized protocols implemented across their global network ensure consistent quality and compliance, which is essential for successful therapeutic outcomes in cell-based therapies.

In addition to cryopreservation, Cryoport Systems offers a comprehensive, integrated supply chain solution that encompasses all aspects of the cell therapy development process. This includes logistics, biostorage, and customized consulting services, all managed under a single vendor relationship. By streamlining these services, Cryoport enhances operational efficiency and mitigates risks associated with handling sensitive biological materials. Their strategic partnerships further bolster their capabilities, providing access to high-quality, manufacture-ready cryopreserved leukopaks, which are crucial for advancing cell and gene therapies globally. This end-to-end approach not only supports the timely development of therapies but also ensures that clients can focus on their core objectives without the complexities of coordinating multiple vendors.

Belgium

Cell Matters is a company operating in the cell therapy industry that enhances cell therapy productivity through cryopreservation services and GMP compliance.

Cell Matters (Cryoport Systems)

Company Details